ArticleInterdisciplinary cardiovascular and thoracic surgery2025
Prosthetic pulmonary valve infectious endocarditis in paediatric congenital heart disease patients.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endocarditis in Adults with Congenital Heart Disease.Methodist DeBakey cardiovascular journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPulmonary valve implantation (PVI) is common in children with congenital heart disease particularly as they get older. While surgical PVI (SPVI) was the mainstay of treatment for years, percutaneous PVI (PPVI) has evolved into a popular treatment option. The aim of our study was to evaluate the rate of prosthetic pulmonary valve infectious endocarditis (PPVIE) between these two modes of intervention.
methodsRetrospective, single-centre review of paediatric patients at a tertiary referral centre from 1993 to 2022 who underwent PVI. Method of intervention (SPVI vs PPVI) and type of pulmonary valve (PV) prosthesis were used as comparison groups. Occurrence of and time interval to the onset of PPVIE were the primary outcomes of interest.
resultsThere were 467 patients who underwent 686 PVIs (665 SPVI [96.9%] and 21 PPVI [3.1%]). The surgical prostheses were all biologic valved conduits: aortic homograft (118, 17.7%), pulmonary homograft (312, 46.9%) and Contegra (235, 35.3%). The percutaneous prostheses were exclusively Melody valves (21, 100.0%). Incidence of PPVIE was 5.1% (35/689) for all PVIs. Annualized incidence of PPVIE was 0.37% for all PVs; and 0.09% for aortic homografts, 0.14% for pulmonary homografts, 1.05% for Contegra conduits and 2.93% for Melody valves. Freedom from PPVIE (FPI) was 92.1% at 30.9 years after intervention for all PVIs. Bovine jugular vein (BJV) valves (Contegra and Melody) had an increased risk of PPVIE compared with surgically implanted homograft valves. Method of PVI (PPVI vs SPVI) was less important than the material of which the implanted PV prosthesis was constructed (homograft vs BJV graft).
conclusionsBJV PV prostheses were more prone to infection than homografts, irrespective of method of implantation. Melody valves, though smaller in number of PVIs performed, displayed a trend toward increased rate of PPVIE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.